Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Trellus Health PLC ( (GB:TRLS) ) is now available.
Trellus Health plc has issued 16,438,845 new ordinary shares following the conversion of £50,000 in principal under the second tranche of its secured convertible loan notes. The issuance was slightly scaled back to offset previously over-allotted shares linked to a commitment fee for Alumni Capital LLC, leaving the new shares representing about 0.2% of the company’s capital and deemed not material.
Application has been made for the new shares to be admitted to trading on AIM, with admission expected around 13 March 2026. Following admission, Trellus Health will have 241,612,340 ordinary shares in issue, a figure that establishes the updated base for calculating shareholder voting rights and regulatory disclosure thresholds under FCA transparency rules.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company that provides value-based digital solutions to help patients manage complex chronic conditions through its Trellus Elevate platform. The company integrates proprietary resilience-based methodology, data analytics, and expert coaching, with an initial focus on high-cost gastrointestinal diseases such as inflammatory bowel disease in the U.S. and U.K. markets.
Average Trading Volume: 6,749,239
Technical Sentiment Signal: Sell
Current Market Cap: £1.18M
See more data about TRLS stock on TipRanks’ Stock Analysis page.